Medigene Value Stock - Dividend - Research Selection
Market price: 3,97 EUR
Medigene Fundamental data and company key figures of the share
|Annual reports in EUR|
|Net operating cash flow||-24.786.000|
|Free cash flow||-25.270.000|
|Liabilities & Shareholders equity||74.750.000|
|Diluted shares outstanding||24.562.700|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||118.568.280,00 USD|
|Indices||CDAX,Prime All Share|
|Raw Data Source||IFRS in Millionen EUR|
|Stock Split||2013-09-03,1.0000/4.0000; 2004-10-27,2105.000000/2104.000000; 2004-03-08,1214.000000/1211.000000|
Description of the company
Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.